Skip to main content
ENDRA Life Sciences Inc. logo

ENDRA Life Sciences Inc. — Investor Relations & Filings

Ticker · NDRA ISIN · US29273B1044 LEI · 6488380RAKK4NN716I68 US Manufacturing
Open in API
Filings indexed 507 across all filing types
Latest filing 2026-05-28 Regulatory Filings
Country US United States of America
Listing US NDRA

About ENDRA Life Sciences Inc.

https://www.endrainc.com/

ENDRA Life Sciences Inc. is a developer of enhanced ultrasound technologies. The company's core technology is the Thermo-Acoustic Enhanced UltraSound (TAEUS®) platform, designed to enable clinicians to visualize tissue composition and function. The initial application of TAEUS is focused on the early detection and monitoring of liver disease by quantifying fat in the liver. This addresses the clinical need for assessing Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), which are often difficult to diagnose in their early stages. The TAEUS system aims to provide a safe, non-invasive, and cost-effective diagnostic tool that can be used at the point of patient care, offering an alternative to more expensive and less accessible imaging methods.

Recent filings

Filing Released Lang Actions
CURRENT REPORT
Regulatory Filings Classification · 10% confidence The document is a full SEC Form 8-K “Current Report” disclosing entry into a material definitive agreement for a private placement of equity and warrants, unregistered sales of securities, other events regarding Nasdaq listing compliance, and accompanying exhibits. It is a regulatory filing rather than a standalone financial report or specific investor presentation, governance statement, or earnings release. Thus, it is best classified under the general Regulatory Filings category.
2026-05-28 English
REGISTRATION STATEMENT
Share Issue/Capital Change Classification · 82% confidence The provided text is an SEC Form S-8 Registration Statement under the Securities Act of 1933, filed to register an additional 3,200,000 shares of common stock under the company’s 2016 Omnibus Incentive Plan. It’s a filing solely to register new shares for issuance under an employee benefit plan, representing a capital change (new share issuance). This clearly fits the “Share Issue/Capital Change” category (SHA).
2026-05-15 English
QUARTERLY REPORT
Interim / Quarterly Report Q1 2026
2026-05-15 English
8-K - ENDRA Life Sciences Inc. (0001681682) (Filer)
Delisting Announcement Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated April 20, 2026, by ENDRA Life Sciences Inc. The key content is under Item 3.01, which is titled 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.' The document details the company's non-compliance with Nasdaq's minimum stockholders' equity requirement, the history of notifications and extensions, and the company's intention to request a hearing to avoid delisting. This is a regulatory announcement specifically about delisting, not a full financial report or other type of filing. The document length is 7,211 characters, which is sufficient for a detailed announcement but it is clearly focused on delisting. Therefore, the appropriate classification is Delisting Announcement (DLST).
2026-04-21 English
10-K - ENDRA Life Sciences Inc. (0001681682) (Filer)
Annual Report FY 2025
2026-03-31 English
8-K - ENDRA Life Sciences Inc. (0001681682) (Filer)
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 31, 2026, for ENDRA Life Sciences Inc. It announces the issuance of a press release regarding financial results for the quarter and year ended December 31, 2025. The document explicitly states that the press release is furnished as an exhibit and that the information is intended to be furnished, not filed, and is not the full financial report itself. The document length is 4288 characters, which is relatively short and consistent with an announcement rather than a full report. The content matches the typical characteristics of an Earnings Release announcement filed on Form 8-K, which is the initial announcement of quarterly or annual financial results with key highlights only, not the full detailed report. Therefore, the correct classification is Earnings Release (ER).
2026-03-31 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.